
Lauren E Kelly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1229002/publications.pdf Version: 2024-02-01



LALIDEN F KELLV

#	Article	IF	CITATIONS
1	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 2020, 383, 517-525.	13.9	1,081
2	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 2020, 173, 623-631.	2.0	444
3	More Codeine Fatalities After Tonsillectomy in North American Children. Pediatrics, 2012, 129, e1343-e1347.	1.0	334
4	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 2020, 7, ofaa130.	0.4	160
5	Morphine or Ibuprofen for Post-Tonsillectomy Analgesia: A Randomized Trial. Pediatrics, 2015, 135, 307-313.	1.0	141
6	Central Nervous System Depression of Neonates Breastfed by Mothers Receiving Oxycodone for Postpartum Analgesia. Journal of Pediatrics, 2012, 160, 33-37.e2.	0.9	108
7	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Cmaj, 2022, 194, E242-E251.	0.9	103
8	Neonatal Benzodiazepines Exposure during Breastfeeding. Journal of Pediatrics, 2012, 161, 448-451.	0.9	82
9	The ontogeny of P-glycoprotein in the developing human blood–brain barrier: implication for opioid toxicity in neonates. Pediatric Research, 2015, 78, 417-421.	1.1	73
10	Sildenafil for pulmonary hypertension in neonates. The Cochrane Library, 2017, 8, CD005494.	1.5	66
11	Pharmacokinetic studies in children: recommendations for practice and research. Archives of Disease in Childhood, 2018, 103, archdischild-2017-314506.	1.0	55
12	Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. The Cochrane Library, 2017, 2017, CD004339.	1.5	47
13	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa500.	0.4	38
14	A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE, 2013, 8, e70073.	1.1	34
15	Oral Morphine Weaning for Neonatal Abstinence Syndrome at Home Compared with In-Hospital: An Observational Cohort Study. Paediatric Drugs, 2015, 17, 151-157.	1.3	28
16	Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT). Trials, 2019, 20, 161.	0.7	28
17	A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey. Trials, 2016, 17, 536.	0.7	24
18	The pharmacogenetics of codeine pain relief in the postpartum period. Pharmacogenomics Journal, 2015, 15, 430-435.	0.9	23

LAUREN E KELLY

#	Article	IF	CITATIONS
19	Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. Pediatric Research, 2018, 83, 1095-1103.	1.1	19
20	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Canadian Journal of Anaesthesia, 2020, 67, 1201-1211.	0.7	19
21	Putative Association of ABCB1 2677G>T/A With Oxycodone-Induced Central Nervous System Depression in Breastfeeding Mothers. Therapeutic Drug Monitoring, 2013, 35, 466-472.	1.0	17
22	Perinatal health services organization for preterm births: a multinational comparison. Journal of Perinatology, 2017, 37, 762-768.	0.9	17
23	Systematic mixedâ€study review of nonpharmacological management of neonatal abstinence syndrome. Birth, 2019, 46, 428-438.	1.1	17
24	A Core Outcome Set for Neonatal Opioid Withdrawal Syndrome. Pediatrics, 2020, 146, .	1.0	17
25	Reporting of interventions and "standard of care―control arms in pediatric clinical trials: a quantitative analysis. Pediatric Research, 2018, 84, 393-398.	1.1	16
26	ls There a Role for Therapeutic Drug Monitoring With Codeine?. Therapeutic Drug Monitoring, 2012, 34, 249-256.	1.0	15
27	Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. Drugs - Real World Outcomes, 2020, 7, 97-107.	0.7	15
28	Innovative approaches to investigator-initiated, multicentre paediatric clinical trials in Canada. BMJ Open, 2019, 9, e029024.	0.8	14
29	Considerations for adaptive design in pediatric clinical trials: study protocol for a systematic review, mixed-methods study, and integrated knowledge translation plan. Trials, 2018, 19, 572.	0.7	11
30	Medical cannabis in pediatric oncology: a survey of patients and caregivers. Supportive Care in Cancer, 2021, 29, 6589-6594.	1.0	11
31	Forensic Investigation of Methadone Concentrations in Deceased Breastfed Infants. Journal of Forensic Sciences, 2016, 61, 576-580.	0.9	10
32	Cannabis for the Treatment of Attention Deficit Hyperactivity Disorder: A Report of 3 Cases. Medical Cannabis and Cannabinoids, 2022, 5, 1-6.	1.2	10
33	Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review. Trials, 2020, 21, 262.	0.7	9
34	Antibiotics for neonates born through meconium-stained amniotic fluid. The Cochrane Library, 2017, 6, CD006183.	1.5	8
35	Consent and recruitment: the reporting of paediatric trials published in 2012. BMJ Paediatrics Open, 2018, 2, e000369.	0.6	8
36	Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expertÂadvice group. Pediatric Research, 2022, 91, 1069-1077.	1.1	8

LAUREN E KELLY

#	Article	IF	CITATIONS
37	c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper. British Journal of Clinical Pharmacology, 2022, 88, 4997-5016.	1.1	8
38	Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer. Cancer Reports, 2022, 5, e1551.	0.6	8
39	Important issues in the justification of a control treatment in paediatric drug trials. Archives of Disease in Childhood, 2016, 101, 962-967.	1.0	7
40	A Comprehensive List of Items to be Included on a Pediatric Drug Monograph. Journal of Pediatric Pharmacology and Therapeutics, 2017, 22, 48-59.	0.3	6
41	Reporting of data monitoring committees and adverse events in paediatric trials: a descriptive analysis. BMJ Paediatrics Open, 2019, 3, e000426.	0.6	5
42	Are infants exposed to methadone in utero at an increased risk for mortality?. Journal of Population Therapeutics and Clinical Pharmacology, 2012, 19, e160-5.	1.4	5
43	Considerations for clinical trials to study cannabinoids in Canadian children with neurologic disorders. Cmaj, 2018, 190, E1002-E1003.	0.9	4
44	Trial registration in pediatric surgery trials. Journal of Pediatric Surgery, 2018, 53, 1273-1279.	0.8	3
45	Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study. JMIR Research Protocols, 2021, 10, e31281.	0.5	3
46	Non-static framework for understanding adaptive designs: an ethical justification in paediatric trials. Journal of Medical Ethics, 2022, 48, 825-831.	1.0	3
47	Clinician views on and ethics priorities for authorizing medical cannabis in the care of children and youth in Canada: a qualitative study. CMAJ Open, 2022, 10, E196-E202.	1.1	3
48	Response biomarkers in neonatal intervention studies. Pediatric Research, 2018, 83, 425-430.	1.1	2
49	ls your standard, my standard? Why control arm reporting matters in pediatric clinical trials. Pediatric Research, 2020, 88, 544-545.	1.1	2
50	Food hypersensitivity-induced chronic gastrointestinal inflammation in a non-human primate model of diet-induced obesity. PLoS ONE, 2019, 14, e0214621.	1.1	1
51	Messaging and methodological considerations when researching breastfeeding and obesity. European Journal of Clinical Nutrition, 2021, 75, 1523-1525.	1.3	1
52	Neither the "Devil's Lettuce―nor a "Miracle Cure:―The Use of Medical Cannabis in the Care of Children and Youth. Neuroethics, 2022, 15, 1.	1.7	1
53	Pharmacogenomic Predictors of Neonatal Abstinence Syndrome. Therapeutic Drug Monitoring, 2015, 37, 281-282.	1.0	0
54	September ECI biocommentary. Pediatric Research, 2018, 84, 318-318.	1.1	0